Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
Funding & venture capital News
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio's lead candidate, THN391, ...
